← FDA DRUG APPROVALS

FDA ANDA · ANDA077613

ANAGRELIDE HYDROCHLORIDE

Sponsor: RISING

APPLICATION
ANDA077613
TYPE
ANDA
ORIGINAL APPROVAL
2006-06-27
LATEST ACTION
2026-01-14
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

ANAGRELIDE HYDROCHLORIDEDiscontinued
ANAGRELIDE HYDROCHLORIDE EQ 1MG BASE · CAPSULE · ORAL
ANAGRELIDE HYDROCHLORIDEDiscontinued
ANAGRELIDE HYDROCHLORIDE EQ 0.5MG BASE · CAPSULE · ORAL

Approval history

2026-01-14Labeling · Supplement 3 · standardAP
2008-10-23Labeling · Supplement 1AP
2006-06-27OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →